Last reviewed · How we verify

M207 Microneedle System — Competitive Intelligence Brief

M207 Microneedle System (M207 Microneedle System) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Transdermal delivery system.

phase 3 Transdermal delivery system Small molecule Live · refreshed every 30 min

Target snapshot

M207 Microneedle System (M207 Microneedle System) — Zosano Pharma Corporation. M207 is a microneedle patch system designed to deliver drugs transdermally by piercing the skin barrier with microscopic needles.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
M207 Microneedle System TARGET M207 Microneedle System Zosano Pharma Corporation phase 3 Transdermal delivery system

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Transdermal delivery system class)

  1. Zosano Pharma Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). M207 Microneedle System — Competitive Intelligence Brief. https://druglandscape.com/ci/m207-microneedle-system. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing